Pharmacological Modulation of Lipoproteins

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 26 July 2024 | Viewed by 355

Special Issue Editor


E-Mail Website
Guest Editor
National Heart and Lung Institute, Imperial College London, London, UK
Interests: coronary artery disease; hypercholesterolemia; cardioimmunology

Special Issue Information

Dear Colleagues,

Lipoproteins are complex particles with cholesterol esters and triglycerides in their center, surrounded by free cholesterol, phospholipids and apolipoproteins, which facilitate the formation and function of lipoproteins. Plasma lipoproteins can be divided into seven groups based on size, lipid composition, and apolipoproteins (chylomicron, chylomicron remnants, VLDL, IDL , LDL, HDL, and Lp(a)).

Disorders of lipoprotein metabolism often lead to disease in humans, especially in cardiovascular health settings. The sequelae of long-term dyslipoproteinemia often lead to atherosclerotic vascular disease.

Many therapeutics have been developed against the harmful subtype of lipoproteins known as low-density lipoproteins (LDLs) and Lp(a) levels. However, little information is available on the impact of therapeutics on the protective subtype of lipoproteins, the high-density lipoproteins (HDLs).

The aim of this Special Issue is to provide an update on the latest research focused on the pharmacological modulation of lipoproteins and would like to attract the extensive range of papers about drugs and treatments that have been developed to regulate lipoproteins in vitro, in vivo, and through cell-based approaches. Similarly, the study of drugs used against any health condition with an impact on lipoprotein levels is welcome.

Dr. Soumaya Ben-Aicha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipoproteins
  • lipid-lowering drugs
  • hypercholesterolemia
  • LDL
  • HDL
  • health disorder

Published Papers

This special issue is now open for submission.
Back to TopTop